Results 71 to 80 of about 10,432 (237)

Hormone Replacement Therapy Uptake and Discontinuation Trends From 1996‐2023: An Observational Study of the Welsh Population

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To analyse prescribing trends for oral and transdermal hormone replacement therapy (HRT) in Wales from 1996 to 2023, including predictors of discontinuation within one year of initiation. Design Observational study using the Secure Anonymised Information Linkage (SAIL) databank.
Robin Andrews, Arron Lacey, Kate Bache, Emma J. Kidd   +3 more
wiley   +1 more source

What Happens After Menopause (WHAM)? A Progress Report of a Prospective Controlled Study of Women After Pre‐Menopausal Risk‐Reducing Bilateral Salpingo‐Oophorectomy

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Surgical menopause, the removal of both ovaries prior to natural menopause, may impact short‐and long‐term physical and emotional health. An increasingly common cause of surgical menopause is risk‐reducing salpingo‐oophorectomy (RRSO) in those at high inherited risk of ovarian cancer.
Sarah A. L. Price, Pauline M. Maki, Samar R. El Khoudary, Alison Brand, Rakibul M. Islam, Susan M. Domchek, Hadine Joffe, Gita D. Mishra, Katrina M. Moss, Fiona C. Baker, Sabine Braat, John D. Wark, Martha Hickey   +12 more
wiley   +1 more source

Modern progestogens in the treatment of genital endometriosis

Репродуктивная эндокринология
Objective of the review: to evaluate modern approaches to the use of progestogens for the treatment of endometriosis, using literature sources, to provide examples of their effectiveness in global and own practices. Analysis of literary data.
L.B. Markin, O.O. Matvienko
doaj   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Women's and Health Care Professionals' Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Hormone Replacement Therapy (HRT) is used to manage menopausal symptoms, particularly vasomotor symptoms (VMS). HRT prescribing rates are rising, but most women will eventually discontinue. Objectives To explore the experiences of women stopping HRT, why women restart HRT, and the HCPs advising them. Search Strategy Embase, MEDLINE,
Sarah Bunnewell, Sabrina Keating, Jo Parsons, Martha Hickey, Sarah Hillman   +4 more
wiley   +1 more source

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background The transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms ...
Jiawen Dong, Sarah Hillman, Sharon Dixon, Anupa Shah, Radha Venkatakrishnan, Jeremy W. Tomlinson   +5 more
wiley   +1 more source

Prenatal 17‐Alpha‐Hydroxyprogesterone Caproate Exposure in Twins and Childhood Outcomes: 14‐Year Follow‐Up of a Randomised Trial

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective Long‐term child outcomes after intra‐uterine exposure to 17‐alpha‐hydroxyprogesterone caproate (17‐OHPC) versus placebo. Design Follow‐up of the AMPHIA randomised controlled trial assessing neonatal outcomes after weekly 17‐OHPC injections compared to placebo in multiple pregnancies. Setting Multicentre. Population or Sample Children
Emilie V. J. van Limburg Stirum, Marjon A. de Boer, A. C. J. Ravelli, Rik van Eekelen, Aleid G. Leemhuis, Martijn J. J. Finken, Cornelieke S. H. Aarnoudse‐Moens, Anneloes L. van Baar, Noor E. Simons, Rebecca C. Painter, Arianne C. Lim, Ben W. Mol, Eva Pajkrt, Martijn A. Oudijk, Janneke van 't Hooft   +14 more
wiley   +1 more source

The action of ovarian hormones in cardiovascular disease

Biological Research, 2003
The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which ...
RODOLFO A MEDINA, EVELYN ARANDA, CESAR VERDUGO, SUMIE KATO, GARETH I OWEN   +4 more
doaj  

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III, Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To compare the efficacy, safety and tolerability of elagolix with dienogest in women with moderate‐to‐severe endometriosis‐associated pain. Design A multicentre, double‐blind, double‐dummy, randomised, parallel‐group, active‐controlled, non‐inferiority phase III study. Setting Nineteen clinical centres across India.
Sneha Bhoir, Jaldhara Patel, Tushar Palve, Mrinal Kanti Dash, Sweety Saigal, Gourisankar Kamilya, Shalini Srivastava, Kartikbhai Savalia, Tanusree Gupta, Deepa Choudhary, Manohar Rangaswamy, Vidya V Bhatt, Neena Gupta, Malathi Ponnuru, Parul Shah, Apurva Shetty, Shruti Saha, Reshma Quadros, Sucheta Pandit, Dipak Patil, Piyush Patel, Pravin Ghadge, Lalit Lakhwani, Suyog Mehta, Sadhana Joglekar   +24 more
wiley   +1 more source